# Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

> **NCT07510100** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Nanjing IASO Biotechnology Co., Ltd.** · enrollment: 17 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel)

## Key facts

- **NCT ID:** NCT07510100
- **Lead sponsor:** Nanjing IASO Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-10
- **Primary completion:** 2029-08-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07510100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07510100, "Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT07510100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*